In a major shake-up that’s bound to impact millions of patients, CVS Caremark is cutting ties with Eli Lilly’s weight loss drug Zepbound—and making Novo Nordisk’s Wegovy the go-to GLP-1 for obesity treatment. If your insurance runs through CVS Caremark, here’s what’s changing, why it’s happening, and what you should do next.

The landscape of diabetes and obesity management is on the cusp of a significant transformation, driven by the development of oral...

With demand for GLP-1 medications like semaglutide and tirzepatide soaring, clinical trials have quietly become one of the only ways some people can access treatment, especially if they’re uninsured or can’t afford retail prices. But before you go signing up for an experimental dose of the next Ozempic or peptide agonist, there are a few important things to understand. In this article, we'll talk about what clinical trials are, their pros and cons, what to expect, and how to

Retatrutide is being called the “triple threat” of weight loss drugs—and it’s not even on the market yet. Developed by Eli Lilly, the same pharmaceutical giant behind tirzepatide (better known as Mounjaro and Zepbound), this new contender is generating buzz for its potential to help people lose more weight, faster.

The window for GLP-1 compounders to tap dance around the compounding ban is almost closed — and anyone still trying to squeeze through could end up with some bruised fingers. A federal court ruling has backed the FDA’s determination that shortages of Wegovy and Ozempic are officially over, setting up a sharp end to the era of legally available compounded GLP-1s.

Eli Lilly, the pharmaceutical giant, filed a sweeping set of lawsuits in federal court, accusing four telehealth startups—Mochi Health, Fella Health, Empower Pharmacy, and Henry Meds—of illegally selling off-brand, compounded versions of its blockbuster weight-loss and diabetes drugs, Zepbound and Mounjaro.

The battle over compounded versions of blockbuster weight-loss drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro,...